Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-ALPV |
Synonyms | |
Therapy Description |
SGN-ALPV is a an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting the placental alkaline phosphatases ALPP and ALPPL2, linked to monomethyl auristatin E (MMAE), with potential antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 1766). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-ALPV | SGN-ALPV is a an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting the placental alkaline phosphatases ALPP and ALPPL2, linked to monomethyl auristatin E (MMAE), with potential antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 1766). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05229900 | Phase I | SGN-ALPV | A Study of SGN-ALPV in Advanced Solid Tumors | Terminated | USA | SWE | GBR | ESP | CAN | 0 |